NCT06073847View on ClinicalTrials.gov

A Post-Marketing Surveillance Study to Assess the Safety of Fedratinib in Korean Patients With Myelofibrosis

RecruitingOBSERVATIONAL
Enrollment

137

Participants

Timeline

Start Date

June 13, 2023

Primary Completion Date

December 20, 2027

Study Completion Date

December 20, 2027

Conditions
Primary MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia Myelofibrosis
Interventions
DRUG

Fedratinib

According to the approved label

Trial Locations (3)

06178

RECRUITING

Bristol-Myers Squibb YH, Seoul

06234

TERMINATED

Local Institution - 0001, Seoul

RECRUITING

Novotech Laboratory Korea Co., Ltd., Seoul

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY